Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global leader in biopharmaceutical innovation with a market capitalization of $115.3 billion. Known for its expertise in antiviral therapy, oncology and other critical treatment areas, Gilead is dedicated to improving health outcomes, accelerating medical advances and addressing unmet medical needs around the world. .
Companies valued at more than $10 billion are typically classified as large-cap stocks, and Gilead Sciences exemplifies this category due to its significant size, innovation, and industry leadership.
Gilead Sciences stock is currently down 7.4% from its 52-week high of $98.90 on November 11th. However, the stock is up 15.8% over the past three months, significantly outperforming the Healthcare Select Sector SPDR Fund (XLV). , decreased by 6.3% during the same period.
www.barchart.com
Over the long term, GILD stock has gained 16.9% over the past 52 weeks and is up 13.1% year-to-date, outpacing XLV's 7.6% gain in 2024 and its 11.1% return over the past year. .
Confirming the recent bullish trend, GILD has been trading above its 50-day moving average since June and above its 200-day moving average since July.
www.barchart.com
Gilead Sciences shares rose 6.8% following the company's third-quarter earnings report on Nov. 6. The company reported revenue of $7.55 billion, up 7% from the same period last year, exceeding expectations. EPS fell 11.8% to $2.02, but beat Wall Street expectations of $1.58. Additionally, Gilead raised its full-year earnings outlook to a range of $4.25 to $4.45 per share, demonstrating confidence in its performance.
Further underscoring Gilead's strong performance is that its competitor, Amgen (AMGN), is lagging behind. Over the past 52 weeks, Amgen's stock price has risen just 2.1% and is down 3.4% year-to-date, compared to Gilead's strong gains.
Analysts are somewhat optimistic about Gilead Sciences' prospects, given its strong price performance. The stock's consensus rating from 30 interviewed analysts is a “moderate buy.” The average price target is $97.92, implying a potential upside of 6.9% from the current price.
On the date of publication, Rashmi Kumari did not have any positions (directly or indirectly) in any securities mentioned in this article. All information and data in this article is for informational purposes only. For more information, please see the Barchart Disclosure Policy here. More news from Barchart
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
